400
Participants
Start Date
September 1, 2023
Primary Completion Date
August 31, 2024
Study Completion Date
October 31, 2025
Filgrastim
G-CSF is a glycoprotein produced by monocytes, fibroblasts, and endothelial cells. Filgrastim is a human granulocyte colony stimulating factor (G-CSF) produced by recombinant DNA technology with NEUPOGEN® as the Amgen Inc. trademark for filgrastim. G-CSF regulates the production, proliferation and differentiation of neutrophils and hematopoietic stem cell precursors within the bone marrow leading to dose-dependent increase in circulating neutrophils and hematopoietic stem cells in the blood. It is indicated to reduce the incidence of infection in patients with severe neutropenia, for neutrophil recovery in neutropenic patients with bone marrow depletion, to mobilize hematopoietic progenitor stem cell for collection by leukapheresis in hematopoietic stem cell transplantation.
NOT_YET_RECRUITING
Oregon Health & Science University (OHSU), Portland
NOT_YET_RECRUITING
Aga Khan University, Karachi
RECRUITING
Nation Children's Hospital, Hanoi
ENROLLING_BY_INVITATION
Children Hospital 1, Ho Chi Minh City
Collaborators (1)
T Rose Clinical, Inc.
UNKNOWN
Big Leap Research
OTHER
Prometheus USA
UNKNOWN
Holterman, Ai-Xuan, M.D.
INDIV